The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety,
tolerability, and antitumor activity of CX-801 as monotherapy and in combination with
pembrolizumab in adult participants with advanced solid tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06462794.
Locations matching your search criteria
United States
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)Status: Active
Name Not Available
The study is comprised of 2 parts. Part 1 involves CX-801 dose escalation to identify the
maximum tolerated dose (MTD) of CX-801 as monotherapy and as combination therapy (CX-801
combined with pembrolizumab). Part 2 (dose expansion) will further assess safety and
tolerability as well as preliminarily assess antitumor activity of CX-801 combination
therapy in indication-specific expansion cohorts.
Lead OrganizationCytomX Therapeutics
Principal InvestigatorMonika Vainorius
